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Abstract
Background: Initiation and modification of antiretroviral therapy in HIV-infected children depend on viral load and CD4+ T-
cell count. However, these surrogates have limitations, and complementary immunological markers to assess therapeutic
response are needed. Our aim was to evaluate CD8+ T-cell expression of CD127 as a marker of disease status in HIV-infected
children, based on adult data suggesting its usefulness. We hypothesized that CD127 expression on CD8+ T-cells is lower in
children with more advanced disease.
Methods: In a cross-sectional evaluation, we used flow cytometry to measure CD127+ expression on CD8+ T-cells in whole
blood from HIV-infected children with varying disease status. This was compared with expression of CD38 on this subset,
currently used in clinical practice as a marker of disease status.
Results: 51 HIV-infected children were enrolled. There was a strong positive correlation between CD127 expression on CD8+
T-cells and CD4+ T-cell count, and height and weight z-scores, and a strong negative correlation between CD127 expression
and viral load. In contrast, we found no association between CD38 expression and these disease status markers.
Conclusions: CD8+ T-cell CD127 expression is significantly higher in children with better HIV disease control, and may have
a role as an immunologic indicator of disease status. Longitudinal studies are needed to determine the utility of this marker
as a potential indicator of HIV disease progression.
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Introduction
Laboratory assessment of HIV disease status is indispensable for
managing antiretroviral therapy in infected children. Initiation
and modification of antiretroviral therapy depend, to a large
extent, on plasma viral load and peripheral blood CD4+ T
lymphocyte count. Although these surrogates for monitoring
disease status are widely used, there are limitations. For example,
the kinetics and extent of antiretroviral-mediated CD4+ T cell
recovery may show great variation from child to child [1].
Similarly, in many settings CD4+ T-cell counts may correlate
poorly with viral replication [1].
There has been a search for complementary immunological
markers to assess or predict response to therapy. In the pediatric
setting, most reports have been generated by relatively small
studies. For example, T-cell expression of HLA-DR, CD38 and
CD95 has been correlated with a poor response to therapy [2,3].
Functional characteristics of T-cells have also been evaluated.
Predominant production of interleukin (IL)-2 by HIV-specific T-
cells may be associated with a favorable response to antiretrovirals,
in contrast to the poorer outcome when IFN-c production is more
prevalent [4–6]. Two studies in the United States of novel
immunological correlates of response to therapy have involved
large numbers of infants and children [5,6]. Both studies found
that a decrease in CD8+ T-cell percentage, and in
CD8+CD38+HLA-DR+ percentage, is associated with a favorable
response to therapy. The authors suggested introduction of such
markers into clinical pediatric practice.
More recently, numerous studies have indicated that T-cell
expression of IL-7 receptor alpha (IL-7Ra or CD127) may be a
predictor of clinical HIV disease status in adults [7–15]. These
studies show that CD127 expression on T-cells is lower in HIV-
infected individuals compared with uninfected controls, and that
this expression correlates inversely with disease severity. Some
reports have suggested that the marker may be useful for
predicting response to therapy [7,9,10], whereas another has
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cytokine crucial for thymopoiesis, maintenance of CD8+ memory
T-cells, and peripheral T-cell homeostasis in states of T-cell
depletion [16–18]. Progressive HIV infection is associated with
increased circulating levels of IL-7, however memory T-cells are
not expanded and homeostasis is not maintained [12,14,19]. IL-7
has been proposed for use as an immunotherapeutic agent for the
treatment of HIV, but the finding of immunologic failure despite
high levels of circulating IL-7 has suggested that this type of
therapy may not be beneficial [20,21]. Dysfunctional CD127
expression [7,22] suggests that failure of the IL-7/IL-7 receptor
system may contribute to the loss of memory T-cell maintenance
in HIV infection. As a result, although there is an increase in
circulating IL-7, lack of its receptor may result in poor
immunological response to IL-7 therapy.
No comprehensive evaluation of CD8+ T-cell expression of
CD127 in HIV-infected children has appeared. A recent study of
37 HIV-infected children showed that CD127 on CD8+ T-cells
correlated directly with CD4+ T-cell frequency [23]. Our cross-
sectional study sought to investigate this correlation, as well as
association with other clinical and immunological surrogates of
disease severity, in a larger group of HIV-infected children.
Results
Study participants
Fifty-one HIV-infected children were enrolled. Three children
were excluded from analysis because of technical problems with
blood processing; 48 remained in the study. A broad spectrum of
HIV disease status and of response to therapy was present among
patients (Table 1). Only two children were not receiving
antiretroviral therapy; both had CD4+ lymphocyte counts in the
normal range and were asymptomatic. Given the broad use of
combination antiretroviral therapy (cART) in our patient popula-
tion, a majority of our study participants had CD4+ T-cell
frequencies in the normal or moderately immunosuppressed range.
Relationship of CD127 expression on CD8+ T-cells with
immunological HIV disease status
Our hypothesis was that IL-7Ra (CD127) expression on CD8+
T-cells (Figure 1) would be a marker of clinical HIV disease status
in infected infants, children and adolescents. We first evaluated the
relationship between CD127 expression and CD4+ T-cell count,
the most widely used immunological surrogate of HIV disease. We
confirmed previous observations that there was a strong
correlation between CD8+ T-cell expression of CD127 and
current CD4+ lymphocyte frequency (Figure 2a) [23]. This
association was much stronger than the expected negative
association between CD4+ lymphocyte frequency and CD38
expression on CD8+ T cells (Figure 2b), a marker which has been
proposed to be a good surrogate of HIV disease status [24].
Similarly, there was a striking association between mean CD127
expression on CD8+ T-cells and current immunologic status
categorized as normal, moderately immunosuppressed or severely
immunosuppressed, according to current CD4+ lymphocyte
frequency (Figure 2c); this association was not present for CD38
expression of CD8+ T cells (Figure 2d).
There was no association between CD127 expression on CD8+
T-cells and CDC ‘‘given’’ immunological classification (data not
shown). This classification reflects the nadir of the CD4+ T cell
count in infants and does not take into account immune
reconstitution that may follow cART.
We concluded that CD127 expression on CD8+ T-cells may be
a more reliable marker of HIV-induced immunosuppression than
CD38+ expression on these cells. Our results further suggested
that CD127 expression on CD8+ T-cells may be a useful indicator
of current HIV disease status, as this marker was a reflection of
current immunological status.
Relationship of CD127 expression on CD8+ T-cells with
HIV viral load
There was a strong negative correlation between CD127
expression on CD8+ T-cells and HIV viral load (Figure 3a), but
CD38 expression on these cells was not associated with viral load
(Figure 3b). CD127 expression was highest in those children with
excellent virologic control (Figure 3c) and lowest in those children
with poor virologic control. No differential pattern could be seen
for CD38 expression (Figure 3d).
Given these findings, we concluded that the close association of
CD127 expression on CD8+ T-cells with HIV viral load further
suggested that this marker may be an immunological surrogate of
HIV disease status.
Relationship of CD127 expression on CD8+ T-cells with
clinical HIV disease status
There was no association between CD127 expression on CD8+
T-cells and ‘‘current’’ CDC classification (Figure 4a). We used
current clinical status, and not each patient’s given CDC
Table 1. Baseline characteristics of 48 HIV-infected children
enrolled into the study.
Age in months (median, range) 147 (29–241)
Male/female ratio 0.5
HIV immunologic stage (n, %)
1 (normal CD4 lymphocyte count) 14 (29%)
2 (moderately immunosuppressed) 12 (25%)
3 (severely immunosuppressed) 22 (46%)
Current CD4+ T cell frequency (n, %)
$ 25% (normal) 34 (71%)
15–24% (moderately immunosuppressed) 8 (16%)
,15% (severely immunosuppressed) 6 (13%)
Current viral load (n, %)
Undetectable 16 (33%)
Up to 10,000 copies/mL 20 (42%)
.10,000 copies/mL 12 (25%)
Participants receiving antiretroviral
therapy (n, %)
46 (96%)
HIV clinical stage (n, %) Given Current
N (asymptomatic) 6 (12%) 22 (46%)
A (mildly symptomatic) 11 (22%) 7 (15%)
B (moderately symptomatic) 15 (31%) 6 (12%)
C (AIDS) 16 (33%) 13 (27%)
‘‘HIV immunologic stage’’ refers to the CDC immunologic classification of the
patient, which reflects their nadir CD4+ T cell frequency, and may be different
from their ‘‘current CD4+ T cell frequency’’. ‘‘Given’’ HIV clinical stage refers to
participants’ CDC classification of symptomatic disease [24]. ‘‘Current’’ HIV
clinical stage reflected application of the CDC classification to symptomatic
disease at the time of study enrollment. The latter classification was useful
because ‘‘given’’ HIV clinical disease stage often reflected previous, severe
disease, while many participants on HAART were clinically well at the time of
enrollment.
doi:10.1371/journal.pone.0003986.t001
IL-7Ra in HIV+ Children
PLoS ONE | www.plosone.org 2 December 2008 | Volume 3 | Issue 12 | e3986Figure 1. Gating strategy for the identification of CD127 expression on CD8+ T cells. Lymphocytes were selected in a forward scatter
height (FSC-H) versus side scatter height (SSC-H) plot. T cells were then selected by gating on CD3+ cells. A–C. Pattern of CD127 expression on CD8+
T-cells in the peripheral blood of 3 of our HIV-infected children with differing CD4+ T-cell frequencies. Results from 3 individual children are shown,
with respective CD8+ lymphocyte frequencies of 3% (A), 23% (B) and 46% (C). The values in brackets represent CD127 expression as a frequency of
total CD8+ T cells. Results shown are gated on CD3+ T cells.
doi:10.1371/journal.pone.0003986.g001
Figure 2. A–B. Association between CD8+ T-cell expression of CD127 (A.) and of CD38 (B.) and CD4+ lymphocyte frequency, in 48 HIV-infected
children. A Spearman test was used to assess correlations. C–D. Relationship of CD8+ T-cell expression of CD127 (C) and of CD38 (D) with degree of
immunosuppression, as categorized by current CD4+ lymphocyte frequency. Mann Whitney test was used to assess differences between the groups.
doi:10.1371/journal.pone.0003986.g002
IL-7Ra in HIV+ Children
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pants were clinically healthier than the given CDC category would
indicate. In this patient population CD38 expression on CD8+ T
cells was also not associated with current clinical disease status
(data not shown), but neither was the best immunologic surrogate
available, CD4+ lymphocyte frequency, associated with clinical
disease status (Figure 4b).
Growth may be one of the best indicators of clinical HIV
disease status in children [25], and correlates well with
immunological and virological parameters to characterize disease
status in HIV-infected children [26]. We were able to demonstrate
that CD127 expression on CD8+ T-cells was higher when height z
scores and weight z scores were higher in our patient population
(Figure 4c–d). We did not see a similar association with CD38
expression (data not shown).
This association with growth parameters further strengthened
the clinical utility of CD127 expression on CD8+ T-cells as a
potential indicator of HIV disease status.
Multivariate analysis of continuous variables that
correlated with CD127 expression on CD8 T-cells
When CD4 T-cell frequency, viral load, weight for age z score,
and height for age z-score were assessed in a multivariate model,
viral load was the only variable that remained negatively
correlated with CD127 expression on CD8+ T-cells (p=0.011).
The bivariate correlation between CD127 expression and the
other 3 variables disappeared (p=0.340, 0.11 and 0.078 for CD4
T-cell frequency, weight for age z-score and height for age z-score,
respectively). The correlation between CD4 T-cell frequency and
CD127 expression disappeared due to the former variable’s strong
correlation with viral load and anthropometric outcomes.
We concluded that there was an independent, strong association
between plasma viral load and CD127 expression on CD8+ T-cells.
Discussion
We showed, in a cross-sectional cohort of HIV-infected
children, that CD127 expression on CD8+ T-cells is lower when
CD4+ T-cell counts are lower, HIV viral loads are higher, and
weight and height for age z scores are lower, all indicators of poor
control of HIV disease. These associations are compelling and
suggest that CD127 expression on CD8+ T-cells could be used
along with CD4+ T-cell counts and HIV viral load as a potential
indicator of disease status in HIV-infected children.
Our results confirmed and expanded on previous observations in
HIV-infected individuals, which have suggested that loss of CD127
expression on CD8+ T-cells may be a correlate of disease progression
[7–15]. These earlier studies showed that lower CD127 expression
occurred both on naı ¨ve and memory T-cells in HIV infection, and
that therewas a strong association with plasmaviremia and CD4+ T-
cell depletion. Additionally, there was a relationship between low
CD127 expression and other T-cell markers suggestive of poor
prognosis. These included markers of immune activation, such as
increased Ki-67 and HLA-DR expression, and markers suggesting
pro-apoptotic activity, such as increased expression of CD95 and
decreased expression of Bcl-2 [7–15].
Longitudinal studies of HIV-infected children are required to
determine whether CD127 expression indeed has utility as another
indicator of HIV disease status or disease progression. These studies
may also be used to determine whether recovery of expression will
occur in response to therapy, as has been suggested in HIV-infected
adults, and to assesswhether, and in what clinical situations, CD127
expression on CD8+ T-cells may be used to guide antiretroviral
Figure 3. A–B. Association between CD8+ T-cell expression of CD127 (A.) and of CD38 (B.) and plasma HIV viral load, in 48 HIV-infected children. The
lower limit of detection of the plasma HIV assay was 400 copies/mL. A Spearman test was used to assess correlations. C.–D. Relationship of CD8+ T-
cell expression of CD127(C) and of CD38 (D) with degree of virologic control, as categorized by the plasma HIV viral load. Mann Whitney test was used
to assess differences between the groups.
doi:10.1371/journal.pone.0003986.g003
IL-7Ra in HIV+ Children
PLoS ONE | www.plosone.org 4 December 2008 | Volume 3 | Issue 12 | e3986therapy. We hypothesize that CD127 expression on CD8+ T-cells
mayhelptoguideclinicalmanagement,particularlywhen CD4+ T-
cell count and viral load findings are discrepant. The promise of
CD127 expression on CD8+ T cells as an immunological correlate
was shown when we compared expression of this marker with that
of CD38 on CD8+ T cells, a more established marker [24,27,28]–
CD127 expression was invariably correlated better with HIV viral
load and CD4+ T cell counts.
CD127 is preferentially expressed on central memory CD4+
and CD8+ T cells, and is progressively lost with advancing HIV
disease [29–31]. Similarly, poor virologic control in chronic
hepatitis B and C infection is associated with loss of this receptor
[32,33]. The ligand for CD127, IL-7, is, together with IL-15,
critical for CD8+ T-cell memory generation and maintenance
[16–18,34]. Therefore, both IL-7 and IL-15 therapy have been
proposed as immunomodulatory therapies in HIV-infected
persons [16,35–37]. Adults with HIV infection already have high
plasma IL-7, and these levels appear to correlate inversely with
CD127 expressed on T-cells [12–14]. It is proposed that, because
IL-7 secretion is relatively constant, serum levels of this cytokine
are determined by availability of target T-cells expressing CD127
[16]. The consistent observation that CD127 expression decreases
with advancing HIV disease therefore raises concerns for IL-7
immunotherapy. Antiretroviral therapy may reverse CD127
expression partially [9], suggesting that IL-7 therapy may be
effective in the presence of this intervention. We hypothesize that
even in this setting measurement of CD127 expression on CD8+
T-cells may prove to be clinically useful marker for predicting
responsiveness to IL-7 administration.
First results of recombinant IL-7 therapy as immunomodulation
in persons with refractory cancer have recently been published
[38]. The results indicate that therapy could enhance and broaden
immune responses, particularly in individuals with limited naive T
cells and diminished TCR repertoire diversity, as occurs in HIV
infection.
Methods
Patient enrollment
In a cross-sectional evaluation, HIV-infected patients were
enrolled from the pediatric HIV clinic of the University of Miami
Miller School of Medicine. Children with any acute illness or with
anemia (hemoglobin#10 g/dL) were excluded. At enrollment,
medical information, including HIV viral loads, CD4+ T-cell
counts and treatment with cART, was obtained from the
participant’s medical record. A physical examination was
performed, including height and weight measurements. The
protocol for this study was approved by the Institutional Review
Board of the University of Miami. Ethical guidelines of the United
States Department of Health and Human Services were followed,
which included written informed parental consent from parents or
guardians, and assent from participants$7 years of age.
Blood collection and processing
Sodium heparinized blood was collected, and FACS Lysing
Solution (BD Biosciences) was added to lyse red cells and fix white
cells. These samples were stored overnight at 4uC, prior to staining
for flow cytometric analysis of T-cell subsets the next day.
Figure 4. A–B. Relationship between CD8+ T-cell expression of CD127 (A), and of CD4+ T-cell frequency (B), with ‘‘current’’ CDC clinical disease
category, in 48 HIV-infected children. ’’Current’’ HIV clinical stage refers to a revised CDC classification, based on symptomatic disease at the time of
study enrollment. Mann Whitney test was used to assess differences between the groups. C.–D. Association between height for age z-score (C) and
weight for age z-score (D) and CD8+ T-cell expression of CD127. A Spearman test was used to assess correlations.
doi:10.1371/journal.pone.0003986.g004
IL-7Ra in HIV+ Children
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yielded flow cytometry results that were identical to those obtained
when fresh, unfixed cells were used. As part of the clinical patient
visit, blood was collected simultaneously for HIV viral load testing
(Amplicor v1.5, Roche, either standard or ultrasensitive at the
discretion of the clinical provider), clinical CD4+ T cell count, and
complete blood count.
Antibodies
Fluorescence-conjugated antibodies against CD45, CD3, CD8,
and CD4 were obtained from BD Biosciences, while a fluores-
cence-conjugated antibody against IL-7Ra (CD127) was obtained
from Beckman-Coulter (clone R34.34).
Flow cytometric analysis of T-cell subsets
Lymphocytes obtained after incubation of the whole blood with
FACS Lysing Solution were pelleted, washed, and stained with
combinations of fluorescence-conjugated antibodies. Two panels
were used to examine cells: (1) CD45, CD3, CD4 and CD8, and
(2) CD3, CD38, CD8, CD127. Acquisition was performed with a
FACS Calibur flow cytometer (BD Biosciences), and further
analysis was completed with FlowJo software (Treestar). In the first
panel, CD4+ and CD8+ lymphocyte and T-cell frequencies were
determined after gating on CD45+ lymphocytes. For the second
panel, frequency of CD127 expression and CD38 expression on
CD8+ T-cells, defined as CD3+ plus CD8+, were measured.
CD127 percentages reflected in figures 2–4 were calculated as a
frequency of the total CD8+ T cell population.
Statistical considerations
All continuous variables that were not normally distributed were
log transformed for analysis. Associations between continuous
measurements were illustrated using two-way scatter plots and
quantified using Spearman’s correlation coefficients. Median
values of continuous responses for different groups of patients
were compared using the Mann-Whitney test. Linear regression
analysis was used to explore predictors of CD127 in a multivariate
setting. Different models were compared using likelihood ratio chi-
square statistics. The participants were evaluated on the basis of
both their ‘‘given’’ and ‘‘current’’ CDC classification. ‘‘Given’’
HIV clinical stage referred to participants’ CDC classification of
symptomatic disease[39]. We assigned the participants a ‘‘current’’
HIV clinical stage based on applying the CDC classification to the
patient’s current symptoms at the time of study enrollment. The
latter classification was useful because ‘‘given’’ HIV clinical disease
stage often reflected previous, severe disease, while many
participants on HAART were clinically well at the time of
enrollment. For example, a patient with a history of an
opportunistic infection at a prior to receiving HAART may have
a ‘‘given’’ CDC clinical category C, but may currently have
improved clinical status and could be considered category A.
Similarly, given that many patients have had immune reconstitu-
tion due to HAART, their ‘‘current’’ immunologic category may
also be different from their ‘‘given’’ CDC classification.
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